Investigational drug · Phase 3
GR1802
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Rhinitis, Seasonal, Allergic Rhinitis, Chronic Rhinosinusitis With Nasal Polyps.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
9
Any phase or sponsor naming "GR1802"
First trial start
2024
Mar 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GR1802", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Rhinitis, Seasonal
- Allergic Rhinitis
- Chronic Rhinosinusitis With Nasal Polyps
Approved drugs for the same conditions: Allergies (allergic rhinitis)
Largest trials
Live from ClinicalTrials.gov: studies naming "GR1802" as an intervention, largest first.
- Phase III Study of GR1802 Injection in Patients With Atopic DermatitisPivotal-lookingStatus unknown
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06216392 · 450 participants (planned) · Start Jan 2024 · Primary completion Jun 2025
Drug: GR1802 injection; placebo · For: Atopic Dermatitis
Sites: Shanghai, China
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).Pivotal-lookingActive, not recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06315426 · 240 participants · Start Mar 24, 2024 · Primary completion May 2025
Drug: GR1802 injection; Placebo · For: Allergic Rhinitis
Sites: Langfang, China; Xingtai, China; Zhengzhou, China · 15 sites in all
- A Study of GR1802 in Participants With Chronic Sinusitis With Nasal PolypsPivotal-lookingCompleted
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06516302 · 228 participants · Start Sep 19, 2024 · Primary completion Jun 12, 2026
Drug: GR1802; Placebo · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Beijing, China
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe AsthmaPivotal-lookingStatus unknown
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06642961 · 150 participants (planned) · Start Jul 19, 2022 · Primary completion Mar 31, 2025
Drug: GR1802 injection; GR1802 injection · For: Asthma
Sites: Guangzhou, China
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic RhinitisPivotal-lookingRecruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07154342 · 150 participants (planned) · Start Aug 15, 2025 · Primary completion Apr 30, 2026
Drug: GR1802 injection; Placebo · For: Allergic Rhinitis, Seasonal
Sites: Wuhan, China
- A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.Pivotal-lookingNot yet recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07199257 · 144 participants (planned) · Start Sep 25, 2025 · Primary completion May 15, 2027
Drug: GR1802 injection; Placebo · For: Allergic Rhinitis, Seasonal
Sites: Wuhan, China
- A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.Status unknown
Zheng Liu ENTAcademic, hospital or other
NCT06028490 · 90 participants (planned) · Start Sep 7, 2023 · Primary completion Nov 2023
Drug: GR1802 injection-1; GR1802 injection-2 and 1 more · For: Allergic Rhinitis
Sites: Wuhan, China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT05873803 · 70 participants (planned) · Start Feb 8, 2023 · Primary completion Oct 30, 2024
Drug: GR1802 injection; placebo · For: Chronic Rhinosinusitis with Nasal Polyps
Sites: Beijing, China
- The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal PolypsStatus unknown
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06015243 · 70 participants (planned) · Start Aug 18, 2023 · Primary completion Dec 30, 2024
Drug: GR1802 injection · For: Chronic Rhinosinusitis With Nasal Polyps
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of IL-4Rα Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials.
Vieira ACP, de Freitas Rezende E, de Jesus ACVS, et al. · Australas J Dermatol 2026
- Targeted biologics for chronic rhinosinusitis with nasal polyps: efficacy and safety comparison of eight monoclonal antibodies via network meta-analysis.
Wang X, Ren P, He H, et al. · Rhinology 2026
- Efficacy and safety of GR1802 in uncontrolled chronic rhinosinusitis with nasal polyps: Placebo-controlled phase 2 trial.
Zheng M, Wu D, Piao Y, et al. · J Allergy Clin Immunol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.